{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Discontinuation",
    "query": {
      "condition": "Drug Discontinuation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Discontinuation&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T00:14:21.354Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04754542",
      "title": "Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2021-05-18",
      "completion_date": "2022-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Kansas City, Kansas • New York, New York + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04754542"
    },
    {
      "nct_id": "NCT01386723",
      "title": "End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Discontinuation of eltrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2011-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-07-17",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01386723"
    },
    {
      "nct_id": "NCT06511882",
      "title": "Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2024-11-07",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06511882"
    },
    {
      "nct_id": "NCT00005001",
      "title": "Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV-1 Immunogen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Agouron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 40,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005001"
    },
    {
      "nct_id": "NCT00890357",
      "title": "Identifying Factors Underlying the Discontinuation of Triptans",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Migraine",
        "Medication Adherence"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 292,
      "start_date": "2009-08",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2013-03-29",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • St Louis, Missouri • Cleveland, Ohio",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00890357"
    },
    {
      "nct_id": "NCT05202301",
      "title": "A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Darolutamide (Nubeqa, BAY1841788)",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13779,
      "start_date": "2022-01-15",
      "completion_date": "2025-07-15",
      "has_results": false,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05202301"
    },
    {
      "nct_id": "NCT06711640",
      "title": "A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Withdrawal (Disorder)",
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "LUCEMYRA (lofexidine) tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "USWM, LLC (dba US WorldMeds)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-06",
      "completion_date": "2026-02",
      "has_results": false,
      "last_update_posted_date": "2025-08-01",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06711640"
    },
    {
      "nct_id": "NCT01826266",
      "title": "Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anticoagulant Reversal",
        "Reversal of Edoxaban Induced Anticoagulation"
      ],
      "interventions": [
        {
          "name": "PER977, Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 83,
      "start_date": "2013-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01826266"
    },
    {
      "nct_id": "NCT01053403",
      "title": "Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "MDMA Discontinuation Syndrome"
      ],
      "interventions": [
        {
          "name": "3,4-methylenedioxymethamphetamine or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Pacific Medical Center Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2010-04",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2013-05-31",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01053403"
    },
    {
      "nct_id": "NCT07387796",
      "title": "Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Drug Discontinuation",
        "Substance Use Disorders",
        "Eating Behavior Changes",
        "Tirzepatide"
      ],
      "interventions": [
        {
          "name": "Discontinuation and Reinitiation of Tirzepatide",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The University of Texas at Dallas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-06",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-06-26T00:14:21.354Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07387796"
    }
  ]
}